Koers Cytori Therapeutics Inc Nasdaq
Aandelen
US23283K1051
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 5,07 mln. 4,72 mln. | Omzet 2025 * | 2,87 mln. 2,67 mln. | Marktkapitalisatie | 8,56 mln. 7,97 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -15 mln. -13,97 mln. | Nettowinst (verlies) 2025 * | -29 mln. -27,01 mln. | EV/omzet 2024 * | 1,69 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,98 x |
K/w-verhouding 2024 * |
-0,72
x | K/w-verhouding 2025 * |
-0,65
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 93,82% |
Recentste transcriptie over Cytori Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Andrew Sims
DFI | Director of Finance/CFO | 51 | 06-02-20 |
Pius Maliakal
CTO | Chief Tech/Sci/R&D Officer | - | 27-07-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 61 | 01-10-02 |
Richard Hawkins
CHM | Chairman | 75 | 01-12-07 |
Robert Lenk
BRD | Director/Board Member | 75 | 01-03-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,59% | 45,51 mld. | |
-9,89% | 38,52 mld. | |
+38,08% | 38,13 mld. | |
+27,12% | 30,74 mld. | |
-8,64% | 26,03 mld. | |
+11,81% | 25,92 mld. | |
+45,08% | 14,13 mld. | |
+32,85% | 12,73 mld. | |
-7,19% | 11,29 mld. |